TherapeuticsMD (NASDAQ:TXMD) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a report issued on Monday, February 4th.
Several other equities research analysts have also weighed in on TXMD. Cantor Fitzgerald set a $27.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, November 7th. Zacks Investment Research raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a report on Wednesday, October 17th. BidaskClub raised shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Saturday, January 5th. Finally, Oppenheimer set a $14.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, November 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $14.45.
TXMD stock traded up $0.22 on Monday, reaching $5.94. 3,449,194 shares of the company were exchanged, compared to its average volume of 2,970,027. TherapeuticsMD has a 12 month low of $3.51 and a 12 month high of $7.66. The firm has a market capitalization of $1.28 billion, a P/E ratio of -10.07 and a beta of 2.06. The company has a current ratio of 7.23, a quick ratio of 7.15 and a debt-to-equity ratio of 0.55.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Thursday, February 21st. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.17). The firm had revenue of $5.09 million for the quarter, compared to analyst estimates of $5.03 million. TherapeuticsMD had a negative net margin of 823.71% and a negative return on equity of 124.70%. Equities research analysts anticipate that TherapeuticsMD will post -0.65 EPS for the current fiscal year.
In other TherapeuticsMD news, insider John C.K. Iv Milligan sold 129,000 shares of the company’s stock in a transaction dated Tuesday, December 4th. The shares were sold at an average price of $4.98, for a total transaction of $642,420.00. Following the transaction, the insider now directly owns 1,601,419 shares in the company, valued at approximately $7,975,066.62. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Brian Bernick sold 182,800 shares of the company’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $5.07, for a total transaction of $926,796.00. Following the transaction, the director now owns 242,000 shares in the company, valued at $1,226,940. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,437,547 shares of company stock worth $6,318,152. 22.85% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in TXMD. California Public Employees Retirement System acquired a new position in TherapeuticsMD during the 2nd quarter valued at about $253,000. Northern Trust Corp raised its position in shares of TherapeuticsMD by 4.0% in the 2nd quarter. Northern Trust Corp now owns 2,086,552 shares of the company’s stock valued at $13,021,000 after acquiring an additional 81,062 shares during the period. Managed Account Services Inc. acquired a new stake in shares of TherapeuticsMD in the 3rd quarter valued at approximately $117,000. First Trust Advisors LP acquired a new stake in shares of TherapeuticsMD in the 3rd quarter valued at approximately $1,139,000. Finally, Wells Fargo & Company MN raised its position in shares of TherapeuticsMD by 12.4% in the 3rd quarter. Wells Fargo & Company MN now owns 244,702 shares of the company’s stock valued at $1,605,000 after acquiring an additional 26,978 shares during the period. Institutional investors own 75.10% of the company’s stock.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Featured Story: Diversification in Investing
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.